Pharmacoepidemiology Study Design & Safety Signal Assessment
Design pharmacoepidemiology studies to assess drug safety signals
What You Can Do
You can design rigorous observational and retrospective cohort studies that meet FDA and EMA regulatory standards, complete with detailed statistical analysis plans and safety assessment frameworks. Claude generates structured study protocols, pre-specifies safety signal detection methodologies, and produces regulatory-ready documentation that accelerates your pathway from research hypothesis to pharmacovigilance submission.
Features
Generate comprehensive protocols with study population definitions, inclusion/exclusion criteria, and outcome specifications aligned with ICH-GCP standards
Systematize adverse event detection using disproportionality analysis, temporal relationship assessment, and dose-response evaluation frameworks
Structure pre-specified statistical approaches including propensity score matching, instrumental variables, and confounder adjustment strategies
Produce agency-ready study synopses, statistical analysis summaries, and safety update narratives formatted for FDA/EMA submission
Develop REMS and risk evaluation frameworks based on signal severity, population vulnerability, and benefit-risk assessment matrices
Generate validation workflows for cohort definitions, outcome classification, and medication exposure ascertainment across healthcare databases
Construct structured frameworks for comparative effectiveness and safety profiling across therapeutic alternatives
Example Output
Study Protocol Excerpt:
- Population: Patients aged ≥18 with diagnosis code [ICD-10] initiating [drug name], excluding prior use in last 12 months
- Primary outcome: Hospitalization for [adverse event], defined by claims/EHR codes [list], with 30-day lookback
- Statistical analysis: Propensity score adjustment using logistic regression (14 baseline covariates), stratified Cox regression with 95% CI estimation
Safety Signal Report:
- Disproportionality: ROR = 2.4 (95% CI: 1.8–3.1) for hepatotoxicity in VigiBase™ 2024 subset
- Temporal assessment: Median onset 45 days post-initiation; rechallenge data supports causality (Naranjo score 7/9)
- Recommendation: Add hepatic impairment to contraindications section; implement liver function monitoring protocol
Regulatory REMS Documentation:
- ETASU requirements: Risk-benefit profile justifies restricted distribution; recommend risk categorization framework and provider certification pathway
What's Included
- SKILL.md: Complete pharmacoepi study design methodology, signal assessment decision trees, and regulatory mapping
- Study Protocol Template: ICH-GCP compliant protocol structure with outcome and covariate specifications
- Safety Signal Assessment Checklist: Disproportionality analysis, temporal relationship, dose-response evaluation workflow
- Statistical Analysis Plan Template: Pre-specified statistical approaches with sensitivity analysis matrices
- Regulatory Submission Framework: FDA Form 1571, EMA CTD safety summary structure, and REMS documentation templates
- Data Quality Validation Checklist: Cohort definition validation, outcome classification verification, exposure ascertainment audit trail
- Comparative Safety Analysis Worksheet: Structured framework for multi-drug safety profiling
- Example Study Protocols: Real-world redacted protocol examples across indication types
Who It's For
- Pharmacoepidemiologists — Design observational studies and execute post-market surveillance programs
- Clinical Safety Officers — Assess emerging safety signals and develop risk minimization strategies
- Regulatory Affairs Specialists — Prepare agency submissions with pre-defined protocols and statistical plans
- Medical Affairs Teams — Support comparative safety assessments and REMS documentation
- Academic Researchers — Develop grant applications and study protocols for drug safety research
Best For
- Designing post-approval pharmacoepidemiology studies for FDA/EMA reporting
- Assessing and characterizing drug safety signals from spontaneous reporting or claims data
- Pre-specifying statistical analysis plans and study protocols before data access
- Developing Risk Evaluation and Mitigation Strategy (REMS) frameworks and justifications
- Conducting comparative safety analyses across competing therapeutic agents
You might also like
Process epidemiological surveillance data in real time to detect disease patterns, anomalies, and emerging threats across multiple jurisdictions. Generate executive-ready federal health briefings with key metrics, risk assessments, and recommended coordination actions for CDC, HHS, and state leadership. Streamline inter-agency communication and accelerate decision-making during outbreak response.
You leverage pharmacoepidemiology methodology to automatically detect potential safety signals from adverse event data, perform statistical significance testing, and generate evidence-based safety characterizations. Claude analyzes disproportionality metrics, temporal trends, and risk stratification to support regulatory decision-making and clinical trial monitoring with peer-reviewed methodology.
You can rapidly design and evaluate evidence-based community health programs that address specific health priorities for your target population. The framework guides you through needs assessment, intervention selection, implementation planning, and evaluation design—helping you create programs that are both effective and equitable. You'll generate detailed implementation roadmaps, resource plans, and sustainability strategies that stakeholders can execute immediately.
You can rapidly structure complex clinical ethical dilemmas using established bioethical frameworks to produce medical-record-ready consultation documentation. This skill maps stakeholder perspectives, identifies competing ethical principles, and delivers defensible recommendations suitable for ethics committees, family meetings, and institutional review—all while ensuring your reasoning withstands legal scrutiny.
You can systematically map ethical tensions inherent in public health policy decisions—such as individual autonomy versus collective benefit, liberty versus security, and efficiency versus equity. This skill identifies which populations bear disproportionate burdens, surfaces hidden value assumptions, and documents ethical reasoning transparent enough to withstand legal scrutiny and build stakeholder trust. You'll produce policy ethics memos suitable for agency leadership, legislative testimony, or public comment.
Coordinate rapid disease outbreak investigations and generate required public health reports. You get structured case management workflows, epidemiological analysis templates, and compliance-ready documentation for state and local health agencies. Streamline investigations, alert protocols, and notification timelines to meet CDC and state reporting requirements.
You develop comprehensive federal public health programs grounded in evidence-based practices and aligned with federal priorities. This skill creates complete strategic plans, needs assessments, logic models, and grant proposals with full compliance documentation. You'll produce implementation roadmaps, budget justifications, and evaluation frameworks that position your programs for competitive federal funding.
This skill helps you investigate emerging health threats across the globe by analyzing outbreak data, identifying patterns, and assessing transmission risks. You can synthesize disease surveillance information, geographic spread analysis, and epidemiological modeling to create comprehensive situation reports that support rapid response decisions.